Evaluate the Benefit of an Individualised Treatment Plan (VitalCare) VS SOC in OSA Patients Treated With CPAP/APAP
- Conditions
- Obstructive Sleep Apnoea Syndrome (OSAS)
- Interventions
- Other: individualised treatment plan (VitalCare) and associated remote medical monitoring
- Registration Number
- NCT05246449
- Lead Sponsor
- Air Liquide Santé International
- Brief Summary
According to a stratification procedure, the objective of a personalised care plan (VitalCare) is to identify points for improvement since the early stage of the patient's pathway of CPAP/APAP treatment and to adjust patient follow-up .
- Detailed Description
It is a prospective, exploratory, randomised, multi-centre, open, controlled study with a 1:1 ratio of two parallel groups, with obstructive sleep apnoea patients starting CPAP/APAP therapy, and receiving by the homecare provider, either an individualised treatment plan (VitalCare) or national standard of care.
This study will be conducted in 5 hospital centres in Portugal..
During a regular medical consultation, eligible patients who have signed their informed consent will be randomised by their investigator.
Two study groups will be set up:
1. Standard of care group
2. VitalCare group
Two medical visits in the hospital centres will be scheduled in the context of the study for all participating patients:
1. A screening/inclusion visit before CPAP/APAP initiation at home;
2. An end-of-study visit planned at 12 months (± 1 month) after CPAP/APAP initiation at home. All visits done in the hospital centres at the discretion of the investigators between patient's screening/inclusion visit and end-of-study visit will be recorded in the eCRF with the reason for the visit and change in CPAP/APAP prescription, if applicable
The primary objective of this study is to evaluate adherence to CPAP/APAP treatment at 3 months in patients with individualised treatment plan (VitalCare) compared to patients with standard of care
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 125
- Patient diagnosed with Obstructive Sleep Apnoea Syndrome (OSAS) who is newly prescribed CPAP or APAP therapy at inclusion
- Patient agreeing to the collection of data from their CPAP/APAP device via teletransmission
- Patient equipped with a device compatible with the ResMed telemonitoring data platform
- Patient who has signed the informed consent form for the study
- Obese patient presenting hypoventilation
- Patient at risk of other sleep disorders (e.g. severe insomnia)
- Patient with physical, mental or cognitive inability to use all components of the remote medical monitoring project and individualised treatment plan, as determined by the investigator wishing to include the patient
- Patient with severe COPD (FEV1 ≤ 50% predicted or modified Medical Research Council (mMRC) dyspnoea scale > 2)
- Patient with severe Chronic Heart Failure (NYHA stage III or IV)
- Patient's refusal of CPAP/APAP treatment support
- Previous CPAP/APAP treatment for Sleep Apnoea
- Patient with ongoing Mandibular Advancement Device (MAD) or in the 12 previous months
- Patient with no permanent place of residence
- Patient participating in another drug or device study within the previous 30 days
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description VitalCare group individualised treatment plan (VitalCare) and associated remote medical monitoring with patients starting their CPAP/APAP treatment and with a personalized follow-up by the homecare provider.
- Primary Outcome Measures
Name Time Method CPAP/APAP adherence evaluation 3rd month average daily number of hours of CPAP/APAP use at 3 months
- Secondary Outcome Measures
Name Time Method adherence to CPAP/APAP 1st, 6th,12th months daily average duration of CPAP/APAP use
evolution of daily Apnoea-Hypopnoea Index (AHI) and Non intentional leaks level teletransmitted by CPAP/APAP devices 1st, 3rd, 6th,12th months Daily Apnoea-Hypopnoea Index (AHI) expressed in average daily number per hour and daily non intentional leaks level expressed in L/min as both median and 95th percentile
adverse events description through study completion, an average of 1 year all adverse events recorded by investigators in the eCRF
daytime sleepiness 1st, 3rd, 6th,12th months The numerical answers obtained for the 8 common daily life situations of the Epworth Sleepiness Scale (ESS) are added to calculate the ESS score each time it is collected
For patients in the VitalCare group, Balachandran CPAP perception questionnaire 1st, 3rd, 6th,12th months The numerical answers obtained for the 4 questions regarding difficulty tolerating CPAP, discomfort with CPAP pressure, likelihood of wearing CPAP, and perceived health benefit are added to calculate the CPAP perception score each time it is collected.
Number of contacts between home healthcare provider and patient 1st, 3rd, 6th,12th months The data files extracted from the home healthcare provider database will allow to count for each study patient, the number of contacts between the home healthcare provider and the patient either i) at home, ii) remotely or iii) in care centres
For patients in the VitalCare group, number of updates of the individualised treatment plan 1st, 3rd, 6th,12th months The data files extracted from the home healthcare provider database will allow to count for each patient from the VitalCare group, the number of updates of the individualised treatment plan
Snoring and Quality of Life 1st, 3rd, 6th,12th months The numerical answers obtained for the 5 questions of the snoring questionnaire are added to calculate the snoring score each time the questionnaire is collected. The numerical answer from 0 to 10 obtained on the Quality of Life visual analogue scale is used each time the questionnaire is collected.
Trial Locations
- Locations (1)
Hospital Distrital de Santarém
🇵🇹Santarém, Portugal